

25<sup>th</sup> April 2024

Corporate Relationship Department  
BSE Limited,  
PJ Towers, Dalal Street,  
Mumbai- 400001

Dear Sirs

**Sub: Outcome of the Board meeting held on 25<sup>th</sup> April 2024- Audited Results and Final Dividend**

**Ref: Script Code: 526783**

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") we wish to inform that the Board of Directors of the Company at its meeting held today i.e. on Thursday, April 25, 2024, commenced at 12.30 p.m. and concluded at 02.00 p.m. inter alia, considered and approved the following:

**i) Audited Financial Results:**

The Audited Financial Results of the Company for the quarter and year ended 31<sup>st</sup> March 2024 and financial results for the quarter ended 31<sup>st</sup> March 2024. Copy of the same is enclosed along with the Reports of the Statutory Auditors thereon and a declaration by the Chief Financial Officer of the Company that the said Reports of Statutory Auditors are with unmodified opinion.

**ii) Final Dividend:**

Recommended a Final dividend of Rs. 2.50/- per equity share of Rs.10/- each fully paid-up, (25%) for the financial year 2023-24 subject to approval of the Members at the ensuing Annual General Meeting. The Dividend shall be paid/ dividend warrant shall be dispatched to the Members within 30 days of its declaration by the Members at the ensuing Annual General Meeting.

The Company has made arrangements for release of the Audited Financial Results for the year ended March 31, 2024 in the newspaper as per the requirement of the SEBI (LODR) Regulation, 2015. Kindly take the above information on record.

Thanking you,

Yours sincerely  
For Dr. Agarwal's Eye Hospital Limited



**Meenakshi Jayaraman**  
Company Secretary and Compliance Officer



Encl: a/a

Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006  
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com



(Amount in INR Crores except EPS)

Statement of Audited Financial Results for the year ended 31st March 2024 and Unaudited Financial Results for the Quarter ended 31st March 2024

S.No.	Particulars	Quarter Ended			Year ended	
		31-Mar-24 (Refer Note 3)	31-Dec-23 Unaudited	31-Mar-23 (Refer Note 3)	31-Mar-24 Audited	31-Mar-23 Audited
1	<b>Income</b>					
	(a) Revenue from Operations	80.72	75.95	69.42	319.30	268.10
	(b) Other Income	2.46	0.67	0.40	4.97	1.55
	<b>Total Income</b>	<b>83.18</b>	<b>76.62</b>	<b>69.82</b>	<b>324.27</b>	<b>269.65</b>
2	<b>Expenses</b>					
	(a) Purchase of Stock-in-Trade	8.85	8.68	7.56	35.95	30.68
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	(0.56)	(0.62)	0.40	(2.25)	(0.87)
	(c) Surgical Lens including other consumables	9.01	9.55	7.98	36.85	31.15
	(d) Consultancy Charges for Doctors	11.72	11.94	9.83	48.37	38.55
	(e) Employee Benefit Expenses	15.41	15.51	14.02	63.78	53.26
	(f) Finance Costs	2.03	1.83	1.81	7.17	6.87
	(g) Depreciation and Amortisation Expense	7.53	6.89	1.54	26.61	20.18
	(h) Other Expenses	11.85	10.12	8.50	45.54	40.43
	<b>Total Expenses</b>	<b>65.84</b>	<b>63.90</b>	<b>51.64</b>	<b>262.02</b>	<b>220.25</b>
3	<b>Profit before tax (1-2)</b>	<b>17.34</b>	<b>12.72</b>	<b>18.18</b>	<b>62.25</b>	<b>49.40</b>
4	<b>Tax Expense</b>					
	- Current Tax	4.70	3.38	3.51	16.22	12.33
	- Deferred Tax (Net)	(0.15)	(0.10)	0.99	(0.33)	0.15
5	<b>Net Profit after tax for the period (3-4)</b>	<b>12.79</b>	<b>9.44</b>	<b>13.68</b>	<b>46.36</b>	<b>36.92</b>
6	<b>Other Comprehensive Income</b>					
	(a) Items that will not be reclassified to the Statement of Profit and Loss					
	- Actuarial (loss) / gain on defined benefit obligation	1.03	(0.33)	0.02	0.05	(0.48)
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	(0.27)	0.09	-	(0.01)	0.13
	<b>Total Other Comprehensive income / (loss) (net of tax)</b>	<b>0.76</b>	<b>(0.24)</b>	<b>0.02</b>	<b>0.04</b>	<b>(0.35)</b>
7	<b>Total Comprehensive Income / (Loss) (5+6)</b>	<b>13.55</b>	<b>9.20</b>	<b>13.70</b>	<b>46.40</b>	<b>36.57</b>
8	Paid-up equity share capital (Face value INR 10/- each)	4.70	4.70	4.70	4.70	4.70
9	Reserves (Other Equity)				152.45	108.64
10	<b>Earnings Per Equity Share (EPS) (Face value of INR 10/- each)</b>					
	(a) Basic	27.21	20.09	29.11	98.64	78.55
	(b) Diluted	27.21	20.09	29.11	98.64	78.55
		(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)	(Annualised)



*Ms. J. S. J.*



**Dr. Agarwal's Eye Hospital Limited**

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com



**Notes:**

- 1 The above financial results have been prepared in accordance with the Indian Accounting Standard ('Ind AS') notified under Section 133 of the Companies Act, 2013, read together with the Companies (Indian Accounting Standards) Rules, 2013 (as amended).
- 2 The above financial results have been reviewed by the Audit Committee and the same has been approved and taken on record by the Board of Directors at their meeting held on 25th April 2024.
- 3 The Financial results for the year ended 31st March 2024 have been audited by the statutory auditors of the Company. The figures for the quarter ended 31st March 2024 and the quarter ended 31st March 2023 are the balancing figures between the audited figures in respect of the financial year ended 31st March 2024 and 31st March 2023 respectively and published year to date figures for the nine months ended 31st December 2023 and 31st December 2022 respectively which were subjected to limited review by the statutory auditors.
- 4 During the period ended 31st March 2023, the Company changed its method of depreciation from written down value for certain categories of assets to straight line method taking into account its reassessment of the expected pattern of economic benefits from those assets. Had the Company continued its previous method of written down value for these assets, depreciation expense for the year ended 31st March 2023 would have been higher by INR 5.58 crores.
- 5 The Company operates in a single segment i.e. "Eye Care related sales and services" and does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.
- 6 Figures for the previous periods, wherever necessary, have been regrouped/ reclassified to conform to the current period's presentation
- 7 The Board of Directors at its meeting held on 25th April 2024 have recommended a final dividend of INR. 2.50 per equity share, subject to the approval of Shareholders.



**By order of the Board**

**Dr. Amar Agarwal**  
Chairman & Managing Director  
DIN No. 00435684

Place : Chennai  
Date : 25 April 2024



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com



(Amount in INR Crores)

Balance Sheet

S.No	Particulars	As at 31st March 2024	As at 31st March 2023
		Audited	Audited
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	Property, Plant and Equipment	120.87	85.31
	Right to Use Assets	193.96	173.92
	Capital Work-In-Progress	97.44	62.21
	Goodwill	0.18	0.18
	Other Intangible Assets	0.62	0.96
	Financial Assets		
	Other Financial Assets	8.50	7.11
	Deferred Tax Assets (Net)	10.03	9.71
	Non Current Tax Assets (Net)	-	0.41
	Other Non-Current Assets	4.33	3.59
	<b>Total Non-Current Assets</b>	<b>435.93</b>	<b>343.40</b>
<b>2</b>	<b>Current Assets</b>		
	Inventories	9.75	6.00
	Financial Assets		
	Trade Receivables	12.93	10.11
	Cash and Cash Equivalents	32.88	27.38
	Bank Balances other than Cash and Cash Equivalents	0.86	0.72
	Other Financial Assets	1.96	2.08
	Other Current Assets	1.45	0.25
	<b>Total Current Assets</b>	<b>59.83</b>	<b>46.54</b>
	<b>Total Assets(1+2)</b>	<b>495.76</b>	<b>389.94</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>3</b>	<b>EQUITY</b>		
	Equity Share Capital	4.70	4.70
	Other Equity	152.45	108.64
	<b>Total Equity</b>	<b>157.15</b>	<b>113.34</b>
<b>4</b>	<b>LIABILITIES</b>		
	<b>Non-Current Liabilities</b>		
	Financial Liabilities		
	Borrowings	44.46	35.77
	Lease Liabilities	203.59	177.97
	Other Financial Liabilities	2.36	1.58
	Provisions	7.43	6.20
	<b>Total Non-Current Liabilities</b>	<b>257.84</b>	<b>221.52</b>



*Agarwal*



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com



(Amount in INR Crores)

Balance Sheet

S.No	Particulars	As at 31st March 2024	As at 31st March 2023
		Audited	Audited
5	<b>Current Liabilities</b>		
	Financial Liabilities		
	Borrowings	6.84	8.06
	Lease Liabilities	13.13	10.67
	Trade Payables		
	- Total outstanding dues of micro enterprises and small enterprises	4.62	2.28
	- Total outstanding dues of creditors other than micro enterprises and small enterprises	27.22	24.41
	Other Financial Liabilities	20.28	4.52
	Other Current Liabilities	5.19	4.10
	Provisions	1.29	1.04
	Current tax liabilities (net)	2.20	-
	<b>Total Current Liabilities</b>	<b>80.77</b>	<b>55.08</b>
	<b>Total Liabilities(4+5)</b>	<b>338.61</b>	<b>276.60</b>
	<b>Total Equity and Liabilities(3+4+5)</b>	<b>495.76</b>	<b>389.94</b>



*M. J. S.*



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com



(Amount in INR Crores)

Cash flow Statement

Particulars	For the year ended 31st March 2024	For the year ended 31st March 2023
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before tax for the period	62.25	49.40
<b>Adjusted for:</b>		
(Profit)/ loss on sale/ discard of property, plant and equipment and other intangible assets (net)	0.23	(0.03)
Allowances for expected credit loss (including bad debts written off)	0.86	0.80
Interest on acquisition liability	0.08	0.14
Depreciation and amortisation expense	26.61	20.18
Net foreign exchange (gain)/ loss	-	0.11
Liabilities/ provisions no longer required written back	(1.72)	(0.24)
Interest income	(1.95)	(0.78)
Finance costs	7.04	6.62
<b>Operating profit before working capital and other changes</b>	<b>93.40</b>	<b>76.20</b>
<b>Adjustments for (increase)/decrease in operating assets:</b>		
Inventories	(3.75)	(0.27)
Trade receivables	(3.71)	(1.98)
Other financial assets - Non current	(0.70)	0.51
Other financial assets - Current	0.46	0.79
Other current assets	(1.20)	2.82
<b>Adjustments for increase/(decrease) in operating liabilities:</b>		
Trade payables	6.86	1.03
Other financial liabilities - Non current	1.26	0.03
Other financial liabilities - Current	8.15	-
Provisions	1.52	1.40
Other current liabilities	1.09	0.61
<b>Cash generated from operations</b>	<b>103.38</b>	<b>81.14</b>
Income Taxes paid (net of refunds)	(13.61)	(11.52)
<b>Net cash generated from operating activities (A)</b>	<b>89.77</b>	<b>69.62</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Capital expenditure towards tangible assets (including capital advances, net of capital creditors)	(71.31)	(70.34)
Proceeds from Sale of Property, Plant and Equipment	1.00	0.07
Capital expenditure towards intangible assets	(0.01)	-
Deferred Consideration Paid	(0.50)	(0.50)
Increase in Bank balances not considered as Cash and cash equivalents	(0.14)	(0.04)
Interest Received on Fixed Deposit	0.92	0.20
<b>Net cash (used in) investing activities (B)</b>	<b>(70.04)</b>	<b>(70.61)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Borrowings	15.00	20.94
Repayment of Borrowings	(7.53)	(9.05)
Dividend paid (including tax thereon)	(2.58)	(1.41)
Finance costs paid on borrowings	(0.23)	(1.78)
Payment of lease liabilities	(18.89)	(8.44)
<b>Net cash generated from/ (used in) financing activities (C)</b>	<b>(14.23)</b>	<b>0.26</b>



Dr. Agarwal's Eye Hospital Limited

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com



(Amount in INR Crores)

Cash flow Statement

Particulars	For the year ended 31st March 2024	For the year ended 31st March 2023
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C) = (D)	5.50	(0.73)
Cash and cash equivalents at the beginning of the period (E)	27.38	28.11
Cash and cash equivalents at the end of the period (D + E) = (F)	32.88	27.38
Cash on hand	0.52	0.57
Balances with Banks	32.36	26.81
Cash and cash equivalents at the end of the period	32.88	27.38

By order of the Board

Dr. Amar Agarwal  
Chairman & Managing Director  
DIN No. 00435684



Place : Chennai  
Date : 25 April 2024





**Dr. Agarwal's Eye Hospital Limited**

CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006

Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

(Amount in INR Crores except EPS)

**Statement of Audited Financial Results for the Year Ended 31st March 2024 and Unaudited Financial Results for the Quarter ended 31st March 2024**

Particulars	Quarter Ended			Year ended	
	31-Mar-24 (Refer Note 2)	31-Dec-23 Unaudited	31-Mar-23 (Refer Note 2)	31-Mar-24 Audited	31-Mar-23 Audited
Revenue from Operations	80.72	75.95	69.42	319.30	268.10
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items )	17.34	12.72	18.18	62.25	49.40
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	17.34	12.72	18.18	62.25	49.40
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	12.79	9.44	13.68	46.36	36.92
Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	13.55	9.20	13.70	46.40	36.57
Paid-up Equity Share Capital (Face Value of INR 10/- each)	4.70	4.70	4.70	4.70	4.70
Reserves (Other Equity)				152.45	108.64
<b>Earnings Per Share (for continuing and discontinued operations) (Face Value of INR 10/- each):</b>					
(a) Basic	27.21	20.09	29.11	98.64	78.55
(b) Diluted	27.21	20.09	29.11	98.64	78.55
	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)	(Annualised)

**Notes:**

1) The above is an extract of the detailed format of Annual Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Annual Audited Financial Results is available on the Stock Exchange website ([www.bseindia.com](http://www.bseindia.com)) and on the Company's website ([www.dragarwal.com](http://www.dragarwal.com)).

2) The Financial results for the year ended 31st March 2024 have been audited by the statutory auditors of the Company. The figures for the quarter ended 31st March 2024 and the quarter ended 31st March 2023 are the balancing figures between the audited figures in respect of the financial year ended 31st March 2024 and 31st March 2023 respectively and published year to date figures for the nine months ended 31st December 2023 and 31st December 2022 respectively which were subjected to limited review by the statutory auditors.

Place : Chennai  
Date : 25 April 2024



By order of the Board

**Dr. Amar Agarwal**  
Chairman & Managing Director  
DIN No. 00435684



**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL FINANCIAL RESULTS  
AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED**

**Opinion and Conclusion**

We have (a) audited the Financial Results for the year ended 31 March 2024 and (b) reviewed the Financial Results for the quarter ended 31 March 2024 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Audited Financial Results for the Year Ended 31 March 2024 and Unaudited Financial Results for the Quarter Ended 31 March 2024" of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

**(a) Opinion on Annual Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, the Financial Results for the year ended 31 March 2024:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

**(b) Conclusion on Unaudited Financial Results for the quarter ended 31 March 2024**

With respect to the Financial Results for the quarter ended 31 March 2024, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Financial Results for the quarter ended 31 March 2024, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Basis for Opinion on the Audited Financial Results for the year ended  
31 March 2024**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Financial Results for the year ended 31 March 2024 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

**Management's Responsibilities for the Statement**

This Statement which includes the Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Financial Results for the year ended 31 March 2024 has been compiled from the related audited financial statements. This responsibility includes the preparation and presentation of the Financial Results for the quarter and year ended 31 March 2024 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.



## **Auditor's Responsibilities**

### **(a) Audit of the Financial Results for the year ended 31 March 2024**

Our objectives are to obtain reasonable assurance about whether the Financial Results for the year ended 31 March 2024 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Financial Results, including the disclosures, and whether the Annual Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Financial Results of the Company to express an opinion on the Annual Financial Results.



Materiality is the magnitude of misstatements in the Annual Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**(b) Review of the Financial Results for the quarter ended 31 March 2024**

We conducted our review of the Financial Results for the quarter ended 31 March 2024 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Other Matters**

- The Statement includes the results for the Quarter ended 31 March 2024 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)



*R. Prasanna Venkatesh*

**R. Prasanna Venkatesh**  
Partner  
Membership No. 214045  
(UDIN: 24214045BKEKKD7235)

Place: Chennai  
Date: 25 April 2024

April 25, 2024

Corporate Relationship Department  
BSE Limited, PJ Towers, Dalal Street,  
Mumbai- 400001

Dear Sirs

**Sub: Declaration in respect of Statutory Auditors Report with Unmodified Opinion- Reg.**  
**Ref: 1) Regulation 33 of the SEBI (LODR) Regulation, 2015**  
**2) Script Code: 526783**

We hereby declare that the Statutory Auditors of the Company M/s. Deloitte Haskins & Sells (Firm Registration Number 008072S), Chartered Accountants, Chennai, have issued the Audit Report with Unmodified Opinion with respect to the Audited Financial Results for the Financial year ended 31<sup>st</sup> March 2024.

Kindly take the above information on record.

Thanking you,

Yours truly

For Dr. Agarwal's Eye Hospital Limited



**B. Udhay Shankar**  
Chief Financial Officer

